Valion Bio, Inc. VBIO
ASignal's systematic analysis rates VBIO as Bearish.
Reflects the latest available analysis · analyzed Sep 25, 2026
The case on VBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI near neutral zone indicating potential for momentum shift
- Positive MACD histogram suggesting improving momentum
- Price above 20-day SMA and Bollinger middle band
- Retail interest visible via 10 Reddit mentions
- Current ratio of 1.11x indicates minimal short-term liquidity pressure
- Negative operating cash flow of $-14.57M
- Free cash flow deeply negative at $-8.06M
- Debt-to-equity ratio of 4.10x indicates high leverage
- Negative price-to-sales and EV-to-revenue multiples suggest valuation distress
- Return on equity of -459.52% reflects severe unprofitability
- Operating margin of 19652.33% is an outlier and likely due to accounting distortions in biotech early-stage firms
See the full verdict on VBIO
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VBIO
Most investors never get a second opinion, let alone several. ASignal runs VBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.